Literature DB >> 17671068

Management guidelines for mucopolysaccharidosis VI.

Roberto Giugliani1, Paul Harmatz, James E Wraith.   

Abstract

Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a lysosomal storage disease that is characterized by systemic clinical manifestations and significant functional impairment. Diagnosis and management are often challenging because of the considerable variability in symptom presentation and rate of progression. The optimal standard of care should be based on evidence from randomized, controlled trials, meta-analyses, systematic reviews, and expert opinion. In support of this goal, comprehensive management guidelines have been drafted by an international group of experts in the management of patients with mucopolysaccharidosis VI. The guidelines provide a detailed outline of disease manifestations by body system, recommendations for regular assessments, and an overview of current treatment options.

Entities:  

Mesh:

Year:  2007        PMID: 17671068     DOI: 10.1542/peds.2006-2184

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  66 in total

1.  Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI.

Authors:  Sean Turbeville; Helen Nicely; J Douglas Rizzo; Tanya L Pedersen; Paul J Orchard; Mitchell E Horwitz; Edwin M Horwitz; Paul Veys; Carmem Bonfim; Amal Al-Seraihy
Journal:  Mol Genet Metab       Date:  2010-10-25       Impact factor: 4.797

2.  Anesthesia in a patient with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).

Authors:  Soon Hak Suh; Ryu Okutani; Masato Nakasuji; Kazuo Nakata
Journal:  J Anesth       Date:  2010-10-26       Impact factor: 2.078

3.  Energy expenditure during gait in patients with mucopolysaccharidosis.

Authors:  Marcos Almeida Matos; André Prado; Gustavo Schenkel; Rosa Barreto; Angelina Xavier Acosta
Journal:  Acta Ortop Bras       Date:  2013-03       Impact factor: 0.513

4.  Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.

Authors:  Roberto Giugliani; Christina Lampe; Nathalie Guffon; David Ketteridge; Elisa Leão-Teles; James E Wraith; Simon A Jones; Cheri Piscia-Nichols; Ping Lin; Adrian Quartel; Paul Harmatz
Journal:  Am J Med Genet A       Date:  2014-04-24       Impact factor: 2.802

5.  Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI.

Authors:  D Sillence; K Waters; S Donaldson; P J Shaw; C Ellaway
Journal:  JIMD Rep       Date:  2011-09-06

Review 6.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

7.  Long-term follow-up of a girl with Maroteaux-Lamy syndrome after bone marrow transplantation.

Authors:  Ching-Chia Wang; Wuh-Liang Hwu; Kai-Hsin Lin
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

8.  Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

Authors:  David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

9.  Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase.

Authors:  Paul Harmatz; Zi-Fan Yu; Roberto Giugliani; Ida Vanessa D Schwartz; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; J Edmond Wraith; Michael Beck; Laila Arash; Maurizio Scarpa; David Ketteridge; John J Hopwood; Barbara Plecko; Robert Steiner; Chester B Whitley; Paige Kaplan; Stuart J Swiedler; Karen Hardy; Kenneth I Berger; Celeste Decker
Journal:  J Inherit Metab Dis       Date:  2010-02-06       Impact factor: 4.982

Review 10.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.